{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-114456","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.507711+00:00","generated_at":"2026-05-22T09:21:40.177595+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"NewAmsterdam Pharma Reports Phase 3 BROADWAY and TANDEM Data Published in NEJM and Lancet","bullets":["BROADWAY trial showed 33% LDL-C reduction (p<0.0001) vs placebo and a 21% relative reduction in MACE (HR=0.79).","TANDEM trial fixed-dose combination of obicetrapib and ezetimibe achieved 48.6% LDL-C reduction vs placebo (p<0.001).","Pooled Lp(a) analysis across three Phase 3 trials showed a median placebo-adjusted reduction of 45% at 12 weeks.","Obicetrapib plus moderate statins lowered LDL-C by 69% (atorvastatin 20 mg) and 64% (rosuvastatin 10 mg) in a Phase 2 trial.","Phase 2 data showed synergy in plaque prevention: combination of obicetrapib and ezetimibe reduced plaque formation by 98% vs 78% independently."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-114456","json":"https://secwatch.observer/filing/0001193125-25-114456.json","markdown":"https://secwatch.observer/filing/0001193125-25-114456.md","text":"https://secwatch.observer/filing/0001193125-25-114456.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312525114456/0001193125-25-114456-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312525114456/d905689d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-22T09:21:40.177595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}